Literature DB >> 29089793

Timeliness of the oncology drug review process for public funding in Canada.

T Younis1,2, C Skedgel3,4.   

Abstract

Year:  2017        PMID： 29089793      PMCID： PMC5659147          DOI： 10.3747/co.24.3825

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  4 in total

1.  Cross-comparison of cancer drug approvals at three international regulatory agencies.

Authors:  N Samuel; S Verma
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

2.  Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

Authors:  J S Hoch; M Sabharwal
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

3.  The politicization of oncology drug funding reviews in Canada.

Authors:  C Skedgel; T Younis
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

4.  Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.

Authors:  A Srikanthan; H Mai; N Penner; E Amir; A Laupacis; M Sabharwal; K K W Chan
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677
  4 in total
  2 in total

Review 1.  Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.

Authors:  Cristiano Ferrario; Anna Christofides; Anil Abraham Joy; Kara Laing; Karen Gelmon; Christine Brezden-Masley
Journal:  Curr Oncol       Date:  2022-04-13       Impact factor: 3.109

2.  Determinants of the Cancer Drug Funding Process in Canada.

Authors:  Joanna Gotfrit; Ashley Jackson; John J W Shin; David J Stewart; Ranjeeta Mallick; Paul Wheatley-Price
Journal:  Curr Oncol       Date:  2022-03-15       Impact factor: 3.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.